ResultsIQ

ResultsIQ › Latest results › Borosil Scientific Limited

Borosil Scientific Limited Q1 FY27 results deck summary

NSE: BOROSCI · BSE: 544184

Results deck of 5 Aug 2026, summarised by AI from the filing.

Borosil Scientific Q1FY27 consolidated net sales ₹106.8 cr (+11.2% YoY) and PAT ₹4.4 cr, with medium-term revenue CAGR target of 12-14%.

Key takeaways

  1. Q1FY27 results Consolidated net sales ₹106.8 cr (Q1FY26: ₹96.0 cr, +11.2%) and PAT ₹4.4 cr (Q1FY26: -₹4.2 cr, +203.5%).
  2. Guidance Management targets revenue CAGR of 12-14% over the medium term.
  3. Change Consolidated EBITDA margin fell to 8.2% in Q1FY27 from 22.7% in Q4FY26.
  4. Driver Pharma Packaging sales grew 31.6% YoY to ₹23.1 cr and Lab Equipment 31.4% to ₹12.3 cr.
  5. Risk Lab Consumables revenue declined 0.1% YoY to ₹45.8 cr, impacted by Ind AS 115.

Original filing on BSE

Borosil Scientific Limited Q1 FY27 results

As filed: Revenue ₹107 cr (+11% year on year), EBITDA ₹8.5 cr (+69% year on year), PAT ₹4.4 cr, EBITDA margin 7.9% (+271 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹143 cr (+11% year on year), EBITDA ₹32.1 cr (+101% year on year), PAT ₹27.3 cr (+203% year on year), EBITDA margin 22.4% (+1,000 bps). Score 79 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Tax rate 7%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +29.6% in 30 days (Nifty 500: +2.8%).
  • Q3 FY26: Revenue ₹121 cr (+20% year on year), EBITDA ₹17.2 cr (+72% year on year), PAT ₹8.7 cr (+108% year on year), EBITDA margin 14.2% (+428 bps). Score 89 of 100, Above trend. EBITDA margin rose 428 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹107 cr (+4% year on year), EBITDA ₹8.0 cr (−47% year on year), PAT ₹3.0 cr (−67% year on year), EBITDA margin 7.5% (−709 bps). Score 0 of 100, Below trend. EBITDA margin fell 709 bps year on year. Other income 40% of PBT. Tax rate 40%. Consolidated profit -67% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.8% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹96.0 cr (−8% year on year), EBITDA ₹5.0 cr (−50% year on year), PAT −₹4.0 cr (−57% year on year), EBITDA margin 5.2% (−441 bps). Score 6 of 100, Below trend. EBITDA margin fell 441 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 26% from last quarter. Share price after the results: −7.5% in 30 days (Nifty 500: +2.8%).
  • Q4 FY25: Revenue ₹118 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 17.8%. Not scored. No result for the same quarter last year. Share price after the results: −4.5% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹94.0 cr, EBITDA ₹11.0 cr, PAT ₹7.0 cr, EBITDA margin 11.7%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹87.0 cr, EBITDA ₹13.0 cr, PAT ₹8.0 cr, EBITDA margin 14.9%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Borosil Scientific Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.